3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Head & Neck
1
Gastrointestinal
1
Conditions
Glioblastoma
6
Neuroblastoma
5
Central Nervous System Neoplasms
5
Gliosarcoma
4
Medulloblastoma
3
Glioma
3
Brain Neoplasms
3
Sarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Pinealoma
2
Ependymoma
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Pyloric Stenosis, Hypertrophic
1
Osteosarcoma
1
Oligodendroglioma
1
Neurofibromatosis 1
1
Neurofibroma
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Histiocytosis, Langerhans-Cell
1
Carcinoma
1
Brainstem Glioma
1
Astrocytoma
1
Interventions
Temozolomide
23
Bevacizumab
18
Cyclophosphamide
9
Carboplatin
7
Lomustine
6
Irinotecan
6
3-Iodobenzylguanidine
6
Topotecan
5
Radiotherapy
5
Filgrastim
5
Radiosurgery
4
Nivolumab
4
Everolimus
4
Etoposide
4
Drug Therapy
4
Busulfan
4
sonidegib
3
pembrolizumab
3
olaparib
3
fludarabine phosphate
3
fludarabine
3
cemiplimab
3
antineoplaston AS 2-1
3
antineoplaston A10
3
Vincristine
3
Thiotepa
3
Sirolimus
3
Melphalan
3
IL13-PE38
3
Antilymphocyte Serum
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recurrence
×
Celecoxib
×
CNS
×
Clear all
NCT02115074
2026-03-18
FLUVABREX
Centre Oscar Lambret
Phase 1
Completed
20 enrolled
NCT01356290
2026-02-23
MEMMAT
Medical University of Vienna
Phase 2
Recruiting
232 enrolled